ISSUE 1329
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue. |
Telavancin (Vibativ– Astellas and Theravance), a lipoglycopeptide derivative of vancomycin (Vancocin, and others), has received FDA approval for treatment of complicated skin and skin structure infections caused by susceptible gram-positive bacteria in adults.
MECHANISM OF ACTION — Telavancin inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane function.
ACTIVITY — In vitro, telavancin is bactericidal against Staphylococcus aureus (including methicillin-resistant strains [MRSA]), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae (including penicillin-resistant isolates), Streptococcus angiosus group, and Enterococcus faecalis (vancomycin-susceptible isolates only).
Medical Letter consultants believe telavancin will prove to have no useful activity against
... more
Would you like to read the rest of this issue? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE